300122 智飞生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入22,786,307-41.98%52,917,76738,264,01130,652,41615,190,366
减:营业总成本19,685,885-36.80%43,094,35629,049,84418,466,48511,179,800
    其中:营业成本16,581,425-41.14%38,674,26225,395,50015,621,8019,268,009
               财务费用54,31154.26%47,21813,79821,821131,384
               资产减值损失(26,398)-77.07%(311,994)(108,868)(92,518)(47,794)
公允价值变动收益--------14,400(13,326)
投资收益--------(20,026)752
    其中:对联营企业和合营企业的投资收益------------
营业利润2,484,711-67.46%9,373,4408,758,38011,999,9733,895,083
利润总额2,477,955-67.48%9,342,2938,718,00811,931,0553,854,072
减:所得税费用327,332-69.94%1,272,4251,179,0081,722,506552,745
净利润2,150,623-67.07%8,069,8687,539,00010,208,5483,301,327
减:非控股权益------------
股东净利润2,150,623-67.07%8,069,8687,539,00010,208,5483,301,327

市场价值指针
每股收益 (元) *0.898-67.01%3.3623.1416.3802.063
每股派息 (元) *0.200--0.8000.5000.6000.500
每股净资产 (元) *13.1355.19%13.12815.14811.0365.155
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容